BUZZ-Natera rises as partners on late-stage cancer trial

Natera, Inc.

Natera, Inc.

NTRA

0.00

** Shares of genetic testing firm Natera NTRA.O rise 3.47% to $270.99

** Co says it has partnered with Aveta Biomics on a late-stage trial for an experimental oral therapy for head and neck cancer

** Aveta says the study will test APG-157, an experimental immunotherapy designed to help the body fight tumors

** Natera says its Signatera blood test will assess molecular residual disease and treatment response, and serve as a secondary endpoint

** Companies say the test will be used before, during and after treatment to monitor response

** Aveta notes the trial will enroll about 826 patients globally, with enrollment expected to begin in the second half of 2026

** Including session's move, Natera up about 17% YTD



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.